Synlogic stock.

Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ...

Synlogic stock. Things To Know About Synlogic stock.

Sep 27, 2023 · Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ... Synlogic ( NASDAQ:SYBX ) First Quarter 2023 Results Key Financial Results Net loss: US$15.6m (flat on 1Q 2022). ... It does not constitute a recommendation to buy or sell any stock, ...Mar 24, 2021 · CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802. 24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Sep 28, 2023 · Continue Reading. September 28, 2023. Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism. Continue Reading. September 27, 2023. Synlogic Announces Reverse Stock Split. Continue Reading. September 21, 2023. Synlogic to Participate in Chardan’s Genetic Medicines Conference.

Synlogic and Mirna Therapeutics Agree to Merger. May 16, 2017. PDF Version. – Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines –. – Synlogic Closes $42 Million of Series C Preferred Stock Financing by LeadingBiotechnology Investors –.Sep 27, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.

Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash ...

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ...A rating of 71 puts Synlogic Inc near the top of the Biotechnology industry according to InvestorsObserver. Synlogic Inc's score of 71 means it scores higher than 71% of stocks in the industry. Synlogic Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 17 out of the 148 industries.A rating of 71 puts Synlogic Inc near the top of the Biotechnology industry according to InvestorsObserver. Synlogic Inc's score of 71 means it scores higher than 71% of stocks in the industry. Synlogic Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 17 out of the 148 industries.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Find the latest Synlogic Inc (MINA.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.

Synlogic Announces Reverse Stock Split Sep 27 2023; SYBX:NAQ price moved over +9.73% to 2.31 Nov 22 2023; SYBX:NAQ price falls below 15-day moving average to 1.98 at 09:52 GMT Nov 24 2023; Key statistics. ... Synlogic, Inc. is a clinical-stage biopharmaceutical company.

Following the reverse split, shares are trading at about $3.95 this morning. SYBX stock is down 5.6% as of Thursday morning, with some 2,000 shares changing hands. For the record, the company’s ...

SYBX one year forecast. Synlogic stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast SYBX stock forecast for 2023 – 2027. Last updated: November 30, 2023. Are you interested in Synlogic, Inc. stocks prediction?But Ginkgo simultaneously invested $80 million in Synlogic at a sizable premium to its stock price at the time. In effect, the money took a round trip, starting as cash in Ginkgo’s bank account ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ...Historical daily share price chart and data for Synlogic since 2015 adjusted for splits and dividends. The latest closing stock price for Synlogic as of November 27, 2023 is 1.97.. …Dec 1, 2023 · Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI 24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Synlogic (SYBX – Research Report), with a price target of $24.00. Ed Arce has given his Buy rating due to a ...Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug ...Synlogic Stock (NASDAQ:SYBX), Quotes and News Summary benzinga.com - February 11 at 9:36 AM Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.

A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The first big announcement that META stock fans will want to note is details on the Meta Quest 3. This is the company’s VR headset that offers 10x the number of pixels as the Meta Quest 2 for $500.

Chg %. Market Cap. Molecular Templates Inc. 4.65%. $33.48M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …SYBX Stock Summary. SYNLOGIC INC's market capitalization of $11,982,884 is ahead of only 7.07% of US-listed equities. As for revenue growth, note that SYBX's revenue has grown -47.85% over the past 12 months; that beats the revenue growth of merely 5.27% of US companies in our set. In terms of volatility of its share price, SYBX is more ...Sep-22-21 11:32PM. Synlogic Announces Pricing of Public Offering of Common Stock. (PR Newswire) Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs.2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Dec 15, 2022 · Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash ... In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Synlogic (SYBX – Research Report), with a price target of $24.00. Ed Arce has given his Buy rating due to a ...Exhibit 10.1 . SYNLOGIC, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED . ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN . 1.1 Purpose and Scope.The purpose of the Synlogic, Inc. 2015 Employee Stock Purchase Plan, as amended, as it may be further amended from time to time, (the “Plan”) is to …Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.

Sep 28, 2023 · Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...

According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.

Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ...Jun 30, 2023 · Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ... The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term ...CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...١٠‏/٠٦‏/٢٠٢١ ... ... Synlogic's stock price peaked above $50/share. In mid-May, however, the price was just a tenth of that, closing on May 24 at less than $4/share.The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Chg %. Market Cap. Molecular Templates Inc. 4.65%. $33.48M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …

According to 2 analysts, the average rating for SYBX stock is "Strong Buy." The 12-month stock price forecast is $82.5, which is an increase of 3,351.88% from the latest price.According to 2 analysts, the average rating for SYBX stock is "Strong Buy." The 12-month stock price forecast is $82.5, which is an increase of 3,351.88% from the latest price.Synlogic ( NASDAQ: SYBX) on Wednesday said it will implement a 1-for-15 reverse stock split of its common stock, effective September 27. The reverse stock split is primarily intended to bring the ...CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.Instagram:https://instagram. ishares russell 1000 value etflist bank stocksgreat pot stockswhen do preorders for iphone 15 start Synlogic Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 1.1%. Looking ahead, revenue is forecast ...The first big announcement that META stock fans will want to note is details on the Meta Quest 3. This is the company’s VR headset that offers 10x the number of pixels as the Meta Quest 2 for $500. s stockscrm stock predictions What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ... shockwave medical news CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B ...CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.